lifestyle.brownplanet.com

Author: Faron Pharmaceuticals

Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

March 11, 2026
Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting

March 9, 2026
New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy

January 29, 2026
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

January 27, 2026
Faron Pharmaceuticals Ltd: PDMR Dealing

January 14, 2026
Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer

December 22, 2025
Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

December 20, 2025
Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in HR-MDS with Favorable Safety Profile

December 8, 2025